Outcomes of treatment of choroidal neovascularization associated with central serous chorioretinopathy with intravitreal antiangiogenic agents

Jay Chhablani, Igor Kozak, Francesco Pichi, Megan Chenworth, Maria H. Berrocal, Rumneek Bedi, Rishi P. Singh, Lihteh Wu, Catherine Meyerle, Antonio Marcelo Casella, Ahmad Mansour, Ziad Bashshur, Antonella Scorza, Paola Carrai, Paolo Nucci, J. Fernando Arevalo

Research output: Contribution to journalArticle

Abstract

Purpose: To report clinical characteristics and treatment outcomes from the largest case series of choroidal neovascularization secondary to central serous chorioretinopathy. Methods: Retrospective analysis of 46 eyes of 43 consecutive subjects. Collected data included demographic details, history of presenting illness, clinical examination details including visual acuity at presentation and follow-up with imaging and treatment details. Main outcome measures were the proportion of eyes that had improved (3 or more lines), stable (within ±1 line), or decreased (3 or more lines) vision at the final visit as compared with baseline examination. Secondary efficacy outcomes included change in visual acuity at final follow-up, number of injections, treatment-free interval, and adverse events. Results: Mean age was 57.56 years (range 29-79 years). Mean follow-up duration was 38.3 months ± 58.9 months. More than 3 lines of improvement in 12 eyes (26%), vision was stable (within ±1 line) in 19 eyes (41.3%), and .3 lines of loss was noted in 6 eyes (13%). Mean change in the number of lines was 1.16 ± 3.74. Mean number of anti-vascular endothelial growth factor injections during the follow-up was 4.45 ± 4.1. The longest treatment-free interval was 8.9 months ± 7.5 months. There were no adverse events noted. Conclusion: Anti-vascular endothelial growth factor therapy as a primary therapy for choroidal neovascularization secondary to central serous chorioretinopathy is safe and efficacious, without any serious adverse events.

Original languageEnglish
Pages (from-to)2489-2497
Number of pages9
JournalRetina
Volume35
Issue number12
DOIs
Publication statusPublished - 2015

Keywords

  • Anti-vascular endothelial growth factor
  • Central serous chorioretinopathy
  • Choroidal neovascularization
  • CNV
  • CSCR

ASJC Scopus subject areas

  • Ophthalmology

Fingerprint Dive into the research topics of 'Outcomes of treatment of choroidal neovascularization associated with central serous chorioretinopathy with intravitreal antiangiogenic agents'. Together they form a unique fingerprint.

Cite this